Placement Pending

Adial Pharmaceuticals placement

US$32m raised

Announced 11 Jun 2026 · NASDAQ: ADIL · US$2.75 cash per share

Advisers

Adial Pharmaceuticals

Issuer

Financial adviser
TD Securities (as TD Cowen)

Lead managers

Placement agent
Issuer
Adial Pharmaceuticals
Issuer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.